Levels of serum lncRNA PITPNA-AS1 and lncRNA NORAD in patients with multiple myeloma and their relationship with prognosis
Objective:To analyze the serum levels of long non-coding RNA(lncRNA)PITPNA antisense RNA1(PITPNA-AS1),lncRNA NORAD in patients with multiple myeloma(MM),and their relationship with prognosis.Methods:96 patients with MM admitted to our hospital and 96 volunteers who came to our hospital for health checkups were selected as the experimental and control groups during January 2018 to December 2020,respective-ly;real-time fluorescence quantitative PCR(RT-qPCR)method was applied to detect the relative expression levels of serum lncRNA PITPNA-AS1 and lncRNA NORAD in two groups;Pearson correlation was applied to analyze the correlation between serum lncRNA PITPNA-AS1 and lncRNA NORAD levels;Kaplan-Meier survival was utilized to analyze the association between serum lncRNA PITPNA-AS1,lncRNA NORAD levels and MM prognosis;multiple Cox regression was utilized to analyze the factors influencing the prognosis of MM patients.Results:The serum lev-els of lncRNA PITPNA-AS1 and lncRNA NORAD in the experimental group were greatly higher than those in the control group(P<0.05).The serum levels of lncRNA PITPNA-AS1 and lncRNA NORAD in patients with stage Ⅲ MM were greatly higher than those in stage Ⅰ and Ⅱ,while the serum levels of lncRNA PITPNA-AS1 and lncRNA NORAD in patients with stage Ⅱ MM were greatly higher than those in stage Ⅰ(P<0.05).There was a positive correlation between serum lncRNA PITPNA-AS1 and lncRNA NORAD levels in patients with MM(r=0.636,P<0.05).Patients with high expression of both lncRNA PITPNA-AS1 and lncRNA NORAD had lower 3-year overall survival than patients with low expression(x2:8.065,11.937;P:0.005,0.001).Higher ISS staging,high levels of lncRNA PITPNA-AS1,and high levels of lncRNA NORAD were prognostic risk factors for MM patients(P<0.05).Conclusion:The serum levels of lncRNA PITPNA-AS1 and lncRNA NORAD are abnormally elevated in patients with MM,and are closely related to prognosis.